80K options granted at $3.12 to Turn Therapeutics (TTRX)

Rhea-AI Filing Summary

Turn Therapeutics Inc. reported that officer Zuraiz Chaudhary received an award of 80,000 employee stock options on April 1, 2026. These options allow the purchase of common stock at an exercise price of $3.12 per share, with no cash paid at grant.

After this award, Chaudhary holds 80,000 stock options directly. The options vest over time: 25% vests on the first anniversary of the grant date and the remaining 75% vests ratably over the following 36 months, subject to continued employment and the terms of the company’s 2025 Omnibus Incentive Plan. This is a compensation grant, not an open‑market share purchase or sale.

Insider Trade Summary

1 transaction reported

Mixed 1 txn

Insider Chaudhary Zuraiz

Role See Remarks

Type	Security	Shares	Price	Value
Grant/Award	Employee stock option (right to buy)	80,000	$0.00	--

Holdings After Transaction: Employee stock option (right to buy) — 80,000 shares (Direct)

Footnotes (1)

1. [object Object]

Key Figures

Option grant size: 80,000 options Exercise price: $3.12 per share Post-grant option holdings: 80,000 options +2 more

5 metrics

Option grant size 80,000 options Employee stock option award to officer on April 1, 2026

Exercise price $3.12 per share Exercise price of employee stock options

Post-grant option holdings 80,000 options Total options held directly after the transaction

Initial vesting tranche 25% of options Vests on first anniversary of grant date

Remaining vesting period 75% over 36 months Ratable vesting after first anniversary, subject to employment

Key Terms

Employee stock option, 2025 Omnibus Incentive Plan, vesting, grant date

4 terms

Employee stock option financial

"Employee stock option (right to buy)"

An employee stock option is a promise that lets a worker buy company shares later at a predetermined price, often after they stay for a certain period or meet performance goals — think of it like a coupon that locks in today's price for a future purchase. It matters to investors because options align employees’ incentives with company performance, can increase the number of shares outstanding (dilution) when exercised, and represent a compensation cost that affects reported profits and shareholder value.

2025 Omnibus Incentive Plan financial

"the Issuer's 2025 Omnibus Incentive Plan"

An omnibus incentive plan is a company-wide program that authorizes awards of pay tied to performance and retention—such as stock options, restricted shares, cash bonuses and other rewards—here labeled for the year it was adopted (2025). Investors care because it affects how much ownership can be issued, dilutes existing shareholders, and aligns executives’ and employees’ incentives with company goals, similar to giving team members a stake in the outcome.

vesting financial

"25% will vest on the first anniversary of the grant date"

Vesting is the process by which you earn full ownership of something, like company stock or a retirement benefit, over time. It’s like earning the right to keep a gift piece by piece the longer you stay with a company, making sure employees stay committed before they receive all the benefits.

grant date financial

"25% will vest on the first anniversary of the grant date"

The grant date is the day a company formally gives an employee or contractor the right to receive stock-based compensation, such as stock options or restricted shares. It matters to investors because it fixes key terms—like the price, the start of the ownership clock, and when the award will affect the company’s financial statements and share count—so it can influence dilution, reported expenses, and potential future selling pressure.

Form 4 Insider Transactions: What Each Field Means →

SEC Form 4

FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL

OMB Number:			3235-0287
Estimated average burden
hours per response:			0.5

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.

1. Name and Address of Reporting Person^*

Chaudhary Zuraiz

(Last) (First) (Middle)

C/O TURN THERAPEUTICS INC.

250 N. WESTLAKE BLVD.

(Street)

WESTLAKE VILLAGE CALIFORNIA 91362

(City) (State) (Zip)

UNITED STATES

(Country)

2. Issuer Name and Ticker or Trading Symbol
Turn Therapeutics Inc. [ TTRX ]

5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)

	Director		10% Owner
X	Officer (give title below)		Other (specify below)
	See Remarks

2a. Foreign Trading Symbol

3. Date of Earliest Transaction (Month/Day/Year)
04/01/2026

6. Individual or Joint/Group Filing (Check Applicable Line)

X	Form filed by One Reporting Person
	Form filed by More than One Reporting Person

4. If Amendment, Date of Original Filed (Month/Day/Year)

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	3. Transaction Code (Instr. 8)		4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5)			5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
			Code	V	Amount	(A) or (D)	Price

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transaction Code (Instr. 8)		5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)		6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)		8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
				Code	V	(A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares
Employee stock option (right to buy)	$3.12	04/01/2026		A		80,000		(1)	(1)	Common Stock	80,000	$0	80,000	D

Explanation of Responses:

1. The option will vest as follows: 25% will vest on the first anniversary of the grant date, with the remaining 75% vesting ratably over the following 36 months, subject to the Reporting Person's continued employment and the terms and conditions of the applicable option award and the Issuer's 2025 Omnibus Incentive Plan.

Remarks:

Interim Chief Financial Officer, Vice President of Finance & Chief Accounting Officer.

	/s/ Zuraiz Chaudhary	04/03/2026
	** Signature of Reporting Person	Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.
* Form 4: SEC 1474 (03-26)

FAQ

What did Turn Therapeutics (TTRX) insider Zuraiz Chaudhary report on this Form 4?

The Form 4 reports that officer Zuraiz Chaudhary received an award of 80,000 employee stock options. These options relate to Turn Therapeutics common stock and are structured as compensation rather than an open-market share purchase or sale.

How many Turn Therapeutics (TTRX) stock options were granted and at what exercise price?

Chaudhary was granted 80,000 employee stock options linked to Turn Therapeutics common stock. Each option carries an exercise price of $3.12 per share, meaning that is the price required to buy a share when the options are exercised in the future.

What is the vesting schedule for Zuraiz Chaudhary’s Turn Therapeutics (TTRX) options?

The options vest over roughly four years. Twenty-five percent vests on the first anniversary of the grant date, and the remaining 75% vests ratably over the following 36 months, conditioned on continued employment and plan terms.

Does this Turn Therapeutics (TTRX) Form 4 show any open-market buying or selling of shares?

No. The filing shows a grant of employee stock options coded as an acquisition award, not open-market buying or selling. It reflects compensation in the form of options rather than trades of existing Turn Therapeutics common shares.

What is the Turn Therapeutics (TTRX) 2025 Omnibus Incentive Plan mentioned in the Form 4?

The 2025 Omnibus Incentive Plan is the company program under which Chaudhary’s 80,000 stock options were granted. Vesting and other terms of the option award are governed by this plan and the related option agreement.

How many Turn Therapeutics (TTRX) options does Zuraiz Chaudhary hold after this transaction?

Following the reported grant, Chaudhary holds 80,000 employee stock options directly. These options give him the right to buy an equal number of Turn Therapeutics common shares at the $3.12 exercise price as they vest.